<i>RAS</i> Mutations Contribute to Evolution of Chronic Myelomonocytic Leukemia to the Proliferative Variant

Clara Ricci(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Francesco Onida(Peter MacCallum Cancer Centre), Alessio Faricciotti(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Mauro Molteni(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Elisa Fermo(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Miloslav Beran(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), Stefania Corti(University of Milan)
Clinical Cancer Research
April 7, 2010
10.1158/1078-0432.ccr-09-2112
Cited by 137

Related Papers

Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology
|Nature Genetics|2021|567
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)
|Blood|2009|433
Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model
|Journal of Clinical Oncology|2015|419
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial
|Journal of Clinical Oncology|2016|394
Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients
|Blood|2014|373